- Home
- TRX vs AVTX Comparison
TRX vs AVTX Comparison
Compare TRX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRX | AVTX |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.9M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | TRX | AVTX |
|---|---|---|
| Price | $0.95 | $19.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $1.25 | ★ $32.29 |
| AVG Volume (30 Days) | ★ 1.6M | 341.4K |
| Earning Date | 01-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $57,613,000.00 | $192,000.00 |
| Revenue This Year | $28.16 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $376.20 | ★ N/A |
| Revenue Growth | ★ 39.98 | N/A |
| 52 Week Low | $0.27 | $3.39 |
| 52 Week High | $0.91 | $20.72 |
Technical Indicators
Market Signals| Indicator | TRX | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.10 | 58.05 |
| Support Level | $0.84 | $18.58 |
| Resistance Level | $0.89 | $20.20 |
| Average True Range (ATR) | 0.05 | 1.60 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 90.04 | 77.65 |
Price Performance
Historical ComparisonAbout TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).